

COVAX

CEPI



unicef



COVAX Allocation Round 11 Vaccine Allocation Decision

IAVG Offline Review – Validated on 05 November 2021

Table of Contents

Background

- ☐ Purpose & Allocation Methodology for Round 11
- ☐ Round 11 Participant Scope
- ☐ Round 11 Supply Scope

Round 11 Proposal

- ☐ Round Outcome - Allocations
- ☐ Descriptive Statistics Summary
- ☐ Overview Graphs
- ☐ Distribution Proposal & Shipment Considerations
- ☐ Conclusions
- ☐ Signatures

IAVG Opinions

- ☐ IAVG Opinion on Current Allocation

Background: Round 11 Supply and Demand

Background

Context for COVAX Allocation Round 11

Context & Purpose

- As new supply from the Serum Institute of India (SII) could potentially be made available to the Facility, COVAX was requested to provide a list of recipients of SII/AZ doses to facilitate discussions around removing the export restrictions to enable the SII to restart shipping doses to COVAX as early as in the coming days or weeks. Allocation Round 11 was therefore run for this purpose.
- The JAT has run COVAX Allocation Round 11 for the allocation of around 25 million doses of SII-AZ (Covishield) for intended delivery in November 2021 to provide the manufacturer with the documentation necessary to approach the Government in negotiations, including list of countries and a related quantity of doses.
- The JAT expects additional volumes of SII-AZ to be confirmed in the coming weeks, once the export authorization will be received for this initial tranche of countries.
- As the volumes are still highly uncertain and confirmation from SII could come at a very late stage, the JAT expects to allocate any additional quantities following the same "non-objection" validation process.

Background

Participant Scope

Participant Scope

COVAX Facility Participants

- There are 89 Advance Market Commitment (AMC) and 73 Self Financing (SFP) participants to the COVAX Facility.
- Among the COVAX Facility Participants, there are 65 AMC and 8 SFP participants are on the list of SII-eligible countries, for a total of 73 Participants.

Round Participant Selection:

- SII has an earmarked list of countries to which Covishield can be commercialized. Out of this set list, participants were selected into this allocation round using total population coverage achieved considering all sources of doses, including those obtained through sources outside of the COVAX Facility, as recorded on the WHO dashboard (<https://covid19.who.int/>) as of 01 November 2021.
- The following participants were excluded from the list of eligible Pax provided by the manufacturer:
 - ☐ participants marking SII vaccine as (highly) undesirable in the COVAX Collaboration Platform (CCP)
 - ☐ participants who have recently communicated to the Facility their intent to refuse this vaccine
 - ☐ participants who have refused this vaccine in the past
 - ☐ participants not ready to receive and use the vaccine in Q4 2021, according to the information received from the "country readiness" teams

Participant Summary	
Criteria	Participants (n)
Inclusion	
AMC	89
OP	40
CP	30
Team Europe	3
Total Participants Included	162
Exclusion	
Outside of SII manufacturer earmark (No combination allowed) (n=89)	<ul style="list-style-type: none">• AMC: 24• SFP: 36 (OP), 26 (CP), 3 (TE)
20% population coverage (or requested) reached through COVAX (n=25)	<ul style="list-style-type: none">• AMC: 25• SFP: 0
Marked SII/AZ as 'undesirable' or 'highly undesirable' in CCP (n=13)	<ul style="list-style-type: none">• AMC: 10• SFP: 2 (OP), 1 (CP)
Refused Earlier Allocation of AZ doses (n=8)	<ul style="list-style-type: none">• AMC: 7• SFP: 1 (CP)
Country readiness-related (n=8)	<ul style="list-style-type: none">• AMC: 8• SFP: 0
Total population coverage (all sources) above 30% (n=3)	<ul style="list-style-type: none">• AMC: 2• SFP: 1 (CP)
Optional Purchaser Participants Owed Other Products (n=2)	<ul style="list-style-type: none">• AMC: 0• SFP: 2 (OP)
Participant-provided allocation caps lower than the minimum product batch size (n=1)	<ul style="list-style-type: none">• AMC: 1• SFP: 0
Voluntary Delay Toggle (n=1)	<ul style="list-style-type: none">• AMC: 1• SFP: 0
Total Participants Excluded	150

Background

COVAX Allocation Round 11 Supply

Round Supply Considerations		Minimum Shipment Size	
<ul style="list-style-type: none">Allocation Round 11 is an exceptional round relying on indicative supply figures provided to the JAT by the COVAX Procurement Coordinator, UNICEF SD, in conjunction with the Gavi Deals Team.The supply is as follow:<ul style="list-style-type: none">❑ 25,275,500 doses of SII-AZ vaccine to allocate through the algorithmThe JAT rushed to allocate these volumes due to the possibility to have the related shipments by the end of this year.		Product Name	Minimum Shipment Size (doses)
		SII-COVISHIELD	<ul style="list-style-type: none">12,000

Background

Humanitarian Buffer

Proposed Allocation to the Humanitarian Buffer	
Product Name	Total Supply (doses)
-	-

Background to Proposed Allocation to the Humanitarian Buffer
<ul style="list-style-type: none">• Due to the special circumstances of this Round, the JAT refrained from allocating doses to the Humanitarian Buffer.• Five percent of R11 supply will, however, count towards what is owed to the Humanitarian Buffer across rounds and caught up in upcoming rounds.

R11 Outcome

R11 Allocation Outcome


Participant Name	WHO Region	Participation Model	Doses allocated of SII
Bangladesh	SEARO	AMC92	3,500,000
Ethiopia	AFRO	AMC92	4,222,500
Guinea	AFRO	AMC92	333,000
Kyrgyzstan	EURO	AMC92	115,000
Lesotho	AFRO	AMC92	219,000
Malawi	AFRO	AMC92	4,841,500
Mozambique	AFRO	AMC92	720,000
Namibia	AFRO	COMMITTED	390,000
Nepal	SEARO	AMC92	6,039,000
Solomon Islands	WPRO	AMC92	150,000
Tajikistan	EURO	AMC92	698,500
Zambia	AFRO	AMC92	4,047,000
Grand Total			25,275,500

R11 Allocation Outcome – Descriptive statistics

Total Participants	AMC92 participants	Committed purchase	Population-weighted avg. coverage in round	Population-weighted avg. coverage overall
12	91.7%	8.3%	3.07%	20.86

	Round Coverage				Total Coverage			
Participation Model ▾	Avg. Coverage in Round ▾	Round Median ▾	Round Min ▾	Round Max ▾	Average ▾	Median ▾	Min ▾	Max ▾
AMC92 participants	5.45	3.661669113	0.88	12.65	22.6	23.52138858	10.93	28.48
Committed purchase	7.67	7.674144038	7.67	7.67	19.99	19.99173554	19.99	19.99
OVERALL	5.63	4.386856965	0.88	12.65	22.38	23.52127831	10.93	28.48

SII allocation output (Round 11)



Distribution Proposal & Shipment Considerations

COVAX Allocation Round 11

Distribution Proposal

- The **median** cumulative coverage from Rounds 1 to 11 for these same 12 participants is **23.52%**.
- Given that this allocation is intended for shipment in late November and early December, should export authorization be obtained, and that Participants allocated SII/AZ in this round have been allocated the product before, Participants are allowed a two-week period to clear all post-allocation preparedness checks following the notification of the Round's outcome.
- Subsequent changes to Participants' total coverage from this Round resulting from the standard reallocation process will be communicated to the Participants upon execution. These modifications will also be visible to the IAVG in the Allocation Portal once completed.

Shipment Considerations

- Should export authorization be obtained, a prioritized shipping order is recommended for distribution of doses allocated in the round. In previous rounds, a decision was taken to inform the sequencing of shipments based on participants' overall achieved coverage from all sources of supply and their epidemiological situation. The JAT will provide this data to the Procurement Coordinator, as has been done in previous rounds.
- The Joint Allocation Taskforce continues to work with the Procurement Coordinator and Procurement Agencies to account for the changing context in Facility Participants, particularly relating to absorptive capacity, upcoming shipments for donations, and additional doses coming from cost-sharing deals.
- The Facility recommends that, closer to the date of the planned shipment, participants' absorption capacity be assessed to ensure that all planned quantities can be used by participants within the vaccines' expiry dates.

Conclusion & Signatures

COVAX Allocation Round 11

Conclusion

By 5 November 2021, eight of the twelve IAVG members validated this allocation on a non-objection basis according to the amounts detailed in **Allocation Round Results** and outlined in the **Round 11 Output** from the WHO Allocation Portal. The JAT provided further information and details as requested by the IAVG during the 24-hours review window.

Eight IAVG Members responded in favor of validating the allocation, therefore achieving quorum, while four IAVG members neither responded to the offline review nor raised objections against the allocation proposal.

Steps

Process Step	Date
The JAT sent R11 indicative allocation proposal to IAVG	04 November 2021
IAVG non-objection validation for R11	05 November 2021
WHO DDG sign-off on R11 allocation decision	05 November 2021
JAT notifies the Office of the COVAX Facility and the Procurement Coordinator	05 November 2021
Country communications dispatched for R11	Beginning on 06 November 2021
IAVG Reports for R11 finalized and published	19 November 2021

Signatures

Signature Assistant Director General, Access to Medicines and Health Products, WHO	Signature Managing Director, Office of the COVAX Facility, Gavi
Provided at COVAX Allocation Leadership Group Meeting	Provided at COVAX Allocation Leadership Group Meeting
Mariângela SIMÃO	Aurélia NGUYEN
On date: 03 November 2021	On date: 03 November 2021

IAVG Opinion

On the JAT Proposed Allocation

The IAVG considered the JAT's allocation proposal and is of the following opinion:

- The IAVG validated the allocation proposal on a non-objection basis to ensure swift distribution of the SII/AZ doses, should export authorization be obtained.
- The IAVG approved the JAT's methodology of:
 - ☐ Focusing the R11 allocation to eligible Participants under 30% total population coverage from all sources;
 - ☐ Ensuring that the allocation went to Participants most likely to accept the SII/AZ product, thereby marking as ineligible to receive those Participants who either refused AZ in the last few months as well as those who marked the product as 'undesirable' or 'highly undesirable' in the COVAX Collaboration Platform (CCP).
- The IAVG welcomes the development that the Serum Institute of India may begin supplying vaccines to the COVAX Facility again.